[1]
K. Erny-Albrecht and E. Erdmann, “Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting”, Swiss Med Wkly, vol. 139, no. 1112, pp. 173–173, Mar. 2009.